Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1047-1052

  Jones, Ronald N ^a,b   Fritsche, Thomas R ^a   Ge, Yigong ^c   Kaniga, Koné ^c   Sader, Helio S ^a,d  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Peninsula Pharmaceuticals   (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti MRSA cephalosporins; MRSA; PPI 0903M

Indexed keywords

CALCIUM; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; PPI 0903M; T 91825; TAK 599; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION CURVE; DRUG SCREENING; ENTEROBACTERIACEAE; IN VITRO STUDY; INOCULATION; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; STANDARD; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; CULTURE MEDIA; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; SERUM;

EID: 29444443515     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki362     Document Type: Article

References (10)

1. Chamberland S, Blais J, Hoang M et al. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant Gram-positive bacteria. Antimicrob Agents Chemother 2001; 45: 1422-30.
2. Fujimura T, Yamano Y, Yoshida I et al. In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 923-31.
3. Jones RN, Deshpande LM, Mutnick AH et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-32.
4. Sader HS, Johnson DM, Jones RN. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant staphylococci and streptococci. Antimicrob Agents Chemother 2004; 48: 53-62.
5. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005: 49: 3501-12.
6. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA caphalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10: 146-56.
7. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
8. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Sixth Edition: Approved Standard M7-A6 NCCLS, Wayne, PA, USA, 2003.
9. Moody J, Knapp C. Time-kill assay. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC, USA: ASM Press, 2004; 5.10.2.1-11.
10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Eighth Edition: Approved Standard M2-A8. NCCLS, Wayne, PA, USA, 2003.